Market capitalization | $49.08m |
Enterprise Value | $40.28m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 2.36 |
P/S ratio (TTM) P/S ratio | 2.88 |
P/B ratio (TTM) P/B ratio | 3.51 |
Revenue (TTM) Revenue | $17.05m |
EBIT (operating result TTM) EBIT | $-34.82m |
As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.
2 Analysts have issued a Bioline RX Ltd Sponsored ADR forecast:
2 Analysts have issued a Bioline RX Ltd Sponsored ADR forecast:
Jun '24 |
+/-
%
|
||
Revenue | 17 17 |
-
|
|
Gross Profit | 11 11 |
1,418%
1,418%
|
|
EBITDA | -33 -33 |
3%
3%
|
EBIT (Operating Income) EBIT | -35 -35 |
2%
2%
|
Net Profit | -30 -30 |
30%
30%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
BioLineRx Ltd. is a clinical stage biopharmaceutical company focused on oncology. The company was founded in April 2003 and is headquartered in Modi'in, Israel.
Head office | Israel |
CEO | Philip Serlin |
Employees | 38 |
Founded | 2003 |
Website | www.biolinerx.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.